RNAi and tumor angiogenesis: Bridging the gap towards anti-cancer therapy?

Leukemia Research

Volumn 31, Issue 4, 2007, Pages 421-422

  Dave, Rajnish S ^a  

^a Center for Human Virology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HOMODIMER; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL; CANCER INHIBITION; CELL MIGRATION; DRUG INHIBITION; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; GENE; HUMAN; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA SPLICING; TUMOR GROWTH; VEGF GENE;

ANIMALS; GENE THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846837655     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.10.024     Document Type: Editorial

References (12)

1. Robinson C.J., Mulloy B., Gallagher J.T., et al. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 281 (2006) 1731-1740
2. Yoo P.S., Mulkeen A.L., and Cha C.H. Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 12 (2006) 4937-4942
3. Stringer S.E. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 34 (2006) 451-453
4. Robinson C.J., and Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 (2001) 853-865
5. Shen H.-L., Xu W.-L., Wu Z.-Y., Qin R.-J., Zhou L.-L., and Tang H.-R. Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leukemia Res 31 (2007) 515-521
6. Filleur S., Courtin A., Ait-Si-Ali S., et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63 (2003) 3919-3922
7. Reich S.J., Fosnot J., Kuroki A., et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9 (2003) 210-216
8. Kwon H.S., Shin H.C., and Kim J.S. Suppression of vascular endothelial growth factor expression at the transcriptional and post-transcriptional levels. Nucl Acids Res 33 (2005) e74
9. Detwiller K.Y., Fernando N.T., Segal N.H., et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 65 (2005) 5881-5889
10. Wannenes F., Ciafre S.A., Niola F., et al. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 12 (2005) 926-934
11. Zhang L., Yang N., Mohamed-Hadley A., et al. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 303 (2003) 1169-1178
12. Matsumoto G., Kushibiki T., Kinoshita Y., et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci 97 (2006) 313-321